UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 551

Sortiert nach

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

NPJ breast cancer, 2023-05, Vol.9 (1), p.45-45, Article 45

2023

Volltextzugriff (PDF)

Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

JNCI : Journal of the National Cancer Institute, 2015-10, Vol.107 (10), p.djv212

Johnston, Stephen R D

2015

Volltextzugriff (PDF)

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

Journal of clinical oncology, 2021-12, Vol.39 (35), p.3959-3977

2021

Volltextzugriff (PDF)

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

Breast cancer research and treatment, 2013, Vol.137 (2), p.471-482

2013

Volltextzugriff (PDF)

New Strategies in Estrogen Receptor―Positive Breast Cancer

Clinical cancer research, 2010-04, Vol.16 (7), p.1979-1987

JOHNSTON, Stephen R. D

2010

Volltextzugriff (PDF)

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

JAMA oncology, 2019-10, Vol.5 (10), p.1473

2019

Volltextzugriff (PDF)

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

Breast cancer research and treatment, 2013-02, Vol.137 (3), p.755-766

2013

Volltextzugriff (PDF)

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer

Therapeutic advances in medical oncology, 2023-01, Vol.15, p.17588359231151840-17588359231151840

2023

Volltextzugriff (PDF)

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

NPJ breast cancer, 2024-04, Vol.10 (1), p.34-34, Article 34

2024

Volltextzugriff (PDF)

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments

Breast cancer research and treatment, 2014-07, Vol.146 (2), p.245-258

2014

Volltextzugriff (PDF)

A review on the added value of whole-body MRI in metastatic lobular breast cancer

European radiology, 2022-09, Vol.32 (9), p.6514-6525

2022

Volltextzugriff (PDF)

Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer

Breast cancer research and treatment, 2014-11, Vol.148 (1), p.221-229

2014

Volltextzugriff (PDF)

Are we missing the mTOR target in breast cancer?

Breast cancer research and treatment, 2011-08, Vol.128 (3), p.607-611

Johnston, Stephen R. D.

2011

Volltextzugriff (PDF)

Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy-Reply

JAMA oncology, 2022-11, Vol.8 (11), p.1702

2022

Volltextzugriff (PDF)

Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer

Frontiers in endocrinology (Lausanne), 2022-03, Vol.13, p.830097

2022

Volltextzugriff (PDF)

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

Breast cancer research and treatment, 2008-07, Vol.110 (2), p.327-335

2008

Volltextzugriff (PDF)

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance

Clinical cancer research, 2010-03, Vol.16 (5), p.1486-1497

2010

Volltextzugriff (PDF)

Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer

Drugs (New York, N.Y.), 2019-11, Vol.79 (17), p.1849-1866

2019

Volltextzugriff (PDF)

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Journal of clinical oncology, 2020-12, Vol.38 (34), p.3987-3998

2020

Volltextzugriff (PDF)

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer

Journal of clinical oncology, 2016-09, Vol.34 (25), p.2961-2968

2016

Volltextzugriff (PDF)

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Clinical cancer research, 2020-10, Vol.26 (19), p.5172-5177

2020

Volltextzugriff (PDF)

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

Clinical cancer research, 2016-12, Vol.22 (24), p.6002-6009

2016

Volltextzugriff (PDF)

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Journal of clinical oncology, 2016-09, Vol.34 (25), p.3069-3103

2016

Volltextzugriff (PDF)

1 – 25 von 551

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(518)
Mit Volltextzugriff
(483)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Estrogen/HER2 receptor crosstalk in breast cancer: combination therapies to improve outcomes for patients with hormone receptor-positive/HER2-positive breast cancer

Enhancing Endocrine Therapy for Hormone Receptor-Positive Advanced Breast Cancer: Cotargeting Signaling Pathways

Endocrine Treatment and Targeted Therapy for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer: ASCO Guideline Update

A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer

New Strategies in Estrogen Receptor―Positive Breast Cancer

Assessment of Molecular Relapse Detection in Early-Stage Breast Cancer

A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer

Efficacy and safety results by menopausal status in monarchE: adjuvant abemaciclib combined with endocrine therapy in patients with HR+, HER2−, node-positive, high-risk early breast cancer

Impact of dose reductions on adjuvant abemaciclib efficacy for patients with high-risk early breast cancer: analyses from the monarchE study

Pneumonitis and pulmonary fibrosis associated with breast cancer treatments

A review on the added value of whole-body MRI in metastatic lobular breast cancer

Expression of regulators of mitotic fidelity are associated with intercellular heterogeneity and chromosomal instability in primary breast cancer

Are we missing the mTOR target in breast cancer?

Quantifying Clinical Utility of Adjuvant Abemaciclib in Patients With High-risk Early Breast Cancer Who Received Neoadjuvant Chemotherapy-Reply

Case Report: Neratinib Therapy Improves Glycemic Control in a Patient With Type 2 Diabetes and Breast Cancer

Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial

A phase II, randomized, blinded study of the farnesyltransferase inhibitor tipifarnib combined with letrozole in the treatment of advanced breast cancer after antiestrogen therapy

Lapatinib Restores Hormone Sensitivity with Differential Effects on Estrogen Receptor Signaling in Cell Models of Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer with Acquired Endocrine Resistance

Advances in Endocrine-Based Therapies for Estrogen Receptor-Positive Metastatic Breast Cancer

Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2-, Node-Positive, High-Risk, Early Breast Cancer (monarchE)

Plasma ESR1 Mutations and the Treatment of Estrogen Receptor-Positive Advanced Breast Cancer

ESR1 Mutations and Overall Survival on Fulvestrant versus Exemestane in Advanced Hormone Receptor-Positive Breast Cancer: A Combined Analysis of the Phase III SoFEA and EFECT Trials

Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial

Biomarker Associations with Efficacy of Abiraterone Acetate and Exemestane in Postmenopausal Patients with Estrogen Receptor-Positive Metastatic Breast Cancer

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline

Suchergebnisse filtern